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Abstract
Background: Cell cycle regulators have gain attention as potential targets for anticancer therapy. Palbociclib is a
selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which coordinate the G1-S transition.
Palbociclib is currently approved for the treatment of hormone receptor positive, HER2-negative advanced breast
cancer (BC) in association with letrozole or fulvestrant. In contrast, its efficacy in triple negative BC (TNBC), either
alone or in combined therapies, has not been fully investigated to date.
Methods: Here we evaluated the potential of combining palbociclib with PI3K/mTOR inhibitors in Rb-proficient
TNBC cells comparing different schedules of treatment: simultaneous, sequential, or sequential combined treatment
(pre-incubation with palbociclib followed by exposure to both palbociclib and PI3K/mTOR inhibitors). We assessed
the effects on cell proliferation, cell death, and cell cycle distribution, and looked at the impact of such treatments
on glucose metabolism.
Results: Palbociclib exerted cytostatic effects in Rb-positive TNBC cells, inducing a reversible blockade in G0/G1 cell
cycle phase associated with down-regulation of CDK6, Rb, and c-myc expression and/or activity. Palbociclib
treatment induced AKT signaling, providing a rationale for its combination with PI3K/mTOR inhibitors. The
simultaneous or sequential treatment resulted in an additive inhibition of cell proliferation. On the other hand, the
sequential combined treatment in which palbociclib was maintained also during exposure to PI3K/mTOR inhibitors
gave rise to synergistic anti-proliferative and pro-apoptotic effects, by inhibiting both CDK4/6/Rb/myc and PI3K/
mTOR signaling. Interestingly, the inhibition of the Rb/E2F/myc axis mediated by palbociclib resulted in a significant
down-regulation of glucose metabolism; most importantly, these inhibitory effects were enhanced by the
combination of palbociclib with BYL719 (specific inhibitor of the p110α PI3K-subunit), which promoted a stronger
inhibition of GLUT-1 glucose transporter expression, glucose uptake and consumption in comparison with
individual treatments, under both normoxic and hypoxic conditions.
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Conclusions: Combination of palbociclib with PI3K/mTOR inhibitors may represent a promising therapeutic option
for the treatment of Rb-proficient TNBC, with the sequential combined schedule showing a superior efficacy over
the other schedules. In addition our results demonstrate that the impairment of glucose metabolism may
contribute to the anti-tumor activity of such drug combinations.
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Background
In spite of the multitude of pharmacologic approaches
which have become clinically available during the last
decades and novel screening improvements, breast can-
cer (BC) remains the second leading cause of cancer-
related death among women [1]. BC subtypes are based
on the expression of hormone receptors, i.e. estrogen re-
ceptor (ER) and/or progesterone receptor (PR) (∼75% of
cases), and overexpression/amplification of the human
epidermal growth factor receptor 2 (HER2) (∼20% of
cases, half of which are also positive for hormone recep-
tors). Tumors lacking the expression of such receptors
are commonly referred to as Triple-negative BCs
(TNBCs) (∼5%–10%) [2]. In addition, the development
of gene expression profiling using high-throughput ana-
lysis has provided a molecular classification of BC into
luminal A, luminal B, HER2-enriched, basal-like,
claudin-low, and normal-like subtypes [3]. TNBCs are
mostly basal-like and are associated with high aggressive-
ness and poor prognosis. Due to the lack of druggable tar-
gets, treatment of TNBC is based on chemotherapy and
the identification of new targets is a high clinical priority.
p16INK4 is a cyclin-dependent kinase inhibitor (CDKI),
that blocks the binding site of cyclin D1 on CDK4/6.
Loss of functional p16INK4 gives rise to deregulated
CDK4/6 activity, leading to persistent retinoblastoma
protein (Rb) phosphorylation and increasing cell
proliferation [4]. The loss of p16INK4 has been reported
to occur with higher frequency in TNBC in comparison
with other BC histotypes and has been correlated with the
poor prognosis of TNBC [5]. In addition, the lack of
p16INK4 expression has been associated with the acquisition
of cancer stem cell-like properties and with a reduced re-
sponse of TNBC to paclitaxel treatment [6]. Also the inacti-
vation of Rb, due to both mutation or homozygous loss of
the gene, may be observed in all BC subtypes, with a higher
frequency in TNBC (7–20%) [7, 8].
Palbociclib, an orally-available inhibitor of CDK4
and CDK6, represents the most widely studied com-
pound among cell cycle inhibitors. Palbociclib is a cy-
tostatic drug, which efficiently blocks cell cycle
progression from G1 to S phase by preventing the
CDK4/6-cyclin D1-mediated phosphorylation of Rb
and the subsequent release of the transcription factor
E2F [9].
Palbociclib granted accelerated approval in 2015 for
the treatment of ER-positive, HER2-negative advanced
BC in association with letrozole [10], and in combin-
ation with fulvestrant in patients with ER-positive/
HER2-negative advanced BC with disease progression
following endocrine therapy [11]. Intriguingly, some
early preclinical evidences have been documenting a
possible efficacy of palbociclib in other BC molecular
subvariants, including TNBC cell lines [12]. Based on
the aforementioned considerations, TNBC with a Rb-
positive, p16INK4-negative profile might represent the
subpopulation of TNBC suitable for treatment with
palbociclib.
In addition to a direct effect of palbociclib on sensitive
malignant cells, the mechanism of action of the drug
also suggests a possible role for combinatory schedules
of treatment. In particular, the recently described mech-
anism of palbocicilib-mediated activation of Protein
Kinase B (AKT) signaling [13] provides a strong ration-
ale for the combination with inhibitors of the phosphoi-
nositide 3-kinase/AKT/mammalian target of rapamycin
(PI3K/AKT/mTOR) pathway. This pathway plays a crit-
ical role in the control of cell growth, proliferation, mi-
gration, and metabolism, and, being frequently
deregulated in BC cells, PI3K/mTOR inhibitors are
under evaluation in numerous clinical trials [14].
These preliminary observations represent the bases of
the present work, designed to evaluate the activity of
palbociclib on a panel of TNBC cell lines with regards to
the possible utilization of the drug also in association
with PI3K/mTOR inhibitors. Our findings demonstrated
that the combination of palbociclib with PI3K/mTOR
inhibitors enhances the growth inhibitory effects of the
single agents, and impairs tumor cell metabolism, sug-
gesting new therapeutic strategies to challenge the ag-
gressive behavior of TNBC.
Methods
Cell culture
Human BC cell lines MDA-MB-231, MDA-MB-468,
HCC-38 (all triple negative) and MCF-7 (ERα-positive)
were cultured in RPMI supplemented with 2 mM
glutamine, 10% fetal bovine serum (FBS), and 100 U/ml
penicillin/100 μg/ml streptomycin.
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Cells were purchased from the American Type Culture
Collection (Manassas, VA), which authenticates the phe-
notypes of these cell lines on a regular basis (http://
www.lgcstandards-atcc.org). Hypoxic conditions were
established by placing the cells in a tissue culture incuba-
tor with controlled O2 levels (Binder GmbH, Tuttlingen,
Germany).
Drug treatment
Palbociclib (PD-0332991) was provided by Pfizer (New
York City, NY); NVP-BEZ235, NVP-BYL719, and NVP-
BKM120 (hereafter, referred to as BEZ235, BYL719, and
BKM120) were provided by Novartis Institutes for Bio-
Medical Research (Cambridge, MA). Drugs were pre-
pared in DMSO, and DMSO concentration never
exceeded 0.1% (v/v); equal amounts of the solvent were
added to control cells.
Analysis of cell proliferation, cell death and cell cycle
Cell proliferation was evaluated by counting the cells in
a Bürker hemocytometer with trypan blue exclusion
method and by Crystal Violet (CV) staining as previ-
ously described [15]. The nature of the interaction be-
tween palbociclib and PI3K inhibitors was calculated
using the Bliss additivism model [16]. A theoretical
dose-response curve was calculated for combined inhib-
ition using the equation of Bliss = EA + EB-EA*EB, where
EA and EB are the percent of inhibition versus control
obtained by BYL719, BEZ235 or BKM120 (A) and palbo-
ciclib (B) alone and the E Bliss is the percent of inhib-
ition that would be expected if the combination was
exactly additive. If the combination effect is higher than
the expected Bliss equation value, the interaction is syn-
ergistic, while if the effect is lower, the interaction is an-
tagonistic. Otherwise, the effect is additive and there is
no interaction between the drugs. Cell death was ana-
lyzed by fluorescence microscopy after staining with
Hoechst 3342 and Propidium Iodide (PI) [17]. Distribu-
tion of the cells in the cell cycle was determined as pre-
viously described [18]. Briefly, 5 × 105 cells were
incubated overnight at 4 °C in 1 ml of hypotonic
fluorochrome solution. Analysis was performed with
Coulter EPICS XL-MCL cytometer (Coulter Co., Miami,
FL, USA). Cell-cycle-phase distributions were analyzed
by MultiCycle DNA Content and FCS Express Software
(De Novo Software, Glendale, CA 91203).
Western blotting
Analyses of western blotting were performed as previ-
ously described [19].
Antibodies against p-RbSer780 (#9307), Rb (#9309), cyclin
D1 (#2926), CDK6 (#3136), c-myc (#9402), p-AKTSer473
(#9271), AKT (#9272), p-mTORSer2448 (#2971), mTOR
(#2972), p-ERK1/2Thr202/Tyr204 (#4370), ERK1/2 (#4695),
were from CST (Danvers, MA); anti-p-CDK6Tyr24 (sc-
293,097) was from Santa Cruz Biotechnology,
Incorporated (Dallas, TX). Anti CDKN2A/p16INK4a
(ab81278) and anti-GLUT-1 (ab40084) were from Abcam
(Cambridge, UK). Antibody against HIF-1α (#610959) was
from BD Biosciences (Franklin Lakes, NJ). Anti-β-actin
(#3598) was from BioVision (Milpitas, CA). All the anti-
bodies were used at the recommended dilution of 1:1000.
Horseradish peroxidase-conjugated secondary antibodies
(1:10,000) and chemiluminescence system were from
Millipore (Millipore, MA). Reagents for electrophoresis
and blotting analysis were from BIO-RAD Laboratories
(Hercules, CA).
Quantitative real-time PCR
Total RNA was isolated by RNeasy Mini Kit (Qiagen,
Venlo, Netherlands) and the quantitative real-time poly-
merase chain reaction (PCR) was performed using the
StepOne system instrument (Applied Biosystems) as pre-
viously described [20]. Briefly, samples were amplified
using the following thermal profile: 95 °C for 20 s and
40 cycles of denaturation at 95 °C for 3 s followed by an-
nealing and extension at 60 °C for 30 s. The primer to
specifically amplify GLUT-1 (QT00068957) was obtained
from Qiagen. HPRT1 (QT00059066) and PGK1
(QT00013776) were used as housekeeping genes and
were purchased from Qiagen. The fold change was cal-
culated by the ΔΔCT method.
Glucose uptake and consumption
Glucose uptake was measured as described previously
[21]. Briefly, cells were rinsed with Kreb’s Ringer
HEPES buffer (KRH) and incubated in KRH contain-
ing 1 μCi/ml Deoxy-D-glucose-2-[1,2-3H(N)] (2DG,
PerkinElmer, Waltham, MA) at 37 °C for 5 min.
Then, the cells were quickly rinsed three times in
fresh cold Earle’s solution containing 0.1 mM phlore-
tin (Sigma-Aldrich). Ice-cold trichloroacetic acid
(TCA, 5%) was added and radioactivity in the acid
extracts was measured by liquid-scintillation. Cell
proteins, precipitated by TCA, were dissolved in 0.
5 N NaOH and their concentration determined by a
dye-fixation method (Bio-Rad, Hercules,CA). Glucose
uptake was calculated as pmol of 2DG/mg protein/
5 min and expressed as percent vs control condition.
Glucose levels in the media were determined using a
Glucose (HK) Assay Kit (product code GAHK-20)
(Sigma-Aldrich, St. Louis, MI), according to the man-
ufacturer’s instruction. Glucose consumption was cal-
culated subtracting the glucose amount in the spent
media to glucose in cell-free media. Data were calcu-
lated as mg glucose/mg protein and expressed as per-
cent vs control.
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Statistical analysis
Statistical analyses were carried out using GraphPad
Prism 6.00 software. Statistical significance of differences
among data was estimated by two-tailed Student’s t test.
Comparison among groups was made using analysis of
variance (one-way ANOVA, repeated measures) followed
by Tukey’s post-test.
Results
Effects of palbociclib on cell proliferation and cell cycle
distribution in TNBC cells
We firstly evaluated the effect of palbociclib on cell pro-
liferation in a panel of TNBC cell lines (MDA-MB-231,
MDA-MB-468, HCC38) in comparison with a ER+
luminal-A BC cell line (MCF-7), that reflects the cancer
histotype for which the drug is currently clinically used.
Cell sensitivity to palbociclib can be predicted by the
presence of detectable levels of p-Rb and cyclin D1, and
by a contemporary reduced expression of the cell cycle
inhibitor p16INK4 [22]. As shown in Fig. 1a, MDA-MB-
231, HCC38, and MCF-7 cell lines expressed both p-Rb
as well as cyclin D1, whereas p16INK4 was not
detectable; accordingly, palbociclib inhibited cell
proliferation in these cell models with EC50 values
ranging from 0.3 to 1.4 μM (Fig. 1b). In contrast, MDA-
MB-468 cells, characterized by the loss of Rb and low
expression of cyclin D1, while showing p16INK4
expression, were less sensitive to palbociclib (Fig. 1a,b).
In addition, palbociclib elicited a robust cell cycle
blockade in G0/G1 phase only on sensitive cell models
(80 and 70% of cells in G0/G1 phase for MDA-MB-231
and HCC38, respectively), whereas MDA-MB-468 cells
did not show any variation in the distribution of cells
within cell cycle phases (Fig. 1c).
Then, to investigate the reversibility of palbociclib on
cell cycle, we treated MDA-MB-231 and HCC38 cells
with palbociclib for 24 h, after which the compound was
removed and cell distribution within cell cycle phases
was analyzed at increasing time intervals. After drug re-
moval, the initial blockade in G0/G1 phase was progres-
sively lost and after 24 h the normal distribution of cells
in each cell cycle phase was restored in both cell lines,
thus confirming that the growth-inhibitory effect of pal-
bociclib is reversible (Fig. 1d). We then evaluated the ef-
fect of palbociclib on the expression of cell cycle-related
proteins and observed that the treatment induced a de-
crease of p-Rb, Rb and p-CDK6 levels and a concomi-
tant increase of cyclin D1 levels in a dose- and time-
dependent manner (Fig. 2a,b, respectively). Hypopho-
sphorylation of Rb protein, due to CDK4/6 inhibition, is
known to result in its activation; active Rb maintains
E2F in a repressed state, with consequent inhibition of
downstream gene transcription [8]. Indeed, palbociclib
treatment of MDA-MB-231 and HCC38 cells down-
regulated the expression of myc, which contains E2F-
binding sites in its regulatory region (Fig. 2a,b).
Fig. 1 Palbociclib inhibits cell proliferation through G0/G1 cell cycle arrest. a The expression of cell cycle-related proteins was analyzed by
Western blotting in TNBC and ERα + cells 24 h after seeding. b TNBC and ERα + cell lines were treated with increasing concentrations of
palbociclib (0.01-10 μM); after 72 h cell proliferation was evaluated by CV staining. The EC50 values are shown. c TNBC cells were treated
in absence (ctrl) or presence of 0.5 μM palbociclib. After 24 h the distribution of cells in cell cycle phases was determined by flow cytometry. d MDA-
MB-231(i) and HCC38 (ii) cells were treated with palbociclib 0.5 μM and 1 μM, respectively. After 24 h palbociclib was removed and cell cycle phase
distributions were evaluated by flow cytometry at the indicated time points. ***p < 0.001 vs corresponding G0/G1 ctrl. Results in a are
representative of three independent experiments. Data in b-d are means ±SD of three independent experiments (n = 5)
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Effects of palbociclib in combination with PI3K/mTOR
inhibitors
Since it has been recently reported that palbociclib treat-
ment increases the activation of AKT/mTOR signaling
[13, 23], we evaluated the activation status of this path-
way in MDA-MB-231 and HCC38 cells after dose- and
time-dependent exposure to palbociclib (Fig. 3a,b). Pal-
bociclib induced a dose-dependent up-regulation of the
phosphorylation levels of mTOR and AKT proteins. On
the contrary, no regulatory effects were observed for
ERK-1/2 pathway. The activation of both AKT and
mTOR increased also over time up to 24 h.
These findings prompted us to investigate the efficacy
of combining palbociclib with three PI3K/mTOR inhibi-
tors: BYL719, an inhibitor of the p110α catalytic subunit
of PI3K, BEZ235, a dual PI3K and mTORC1–2 inhibitor,
and BKM120, a pan-class I PI3K inhibitor. The exposure
of TNBC cell lines to these compounds resulted in the
inhibition of cell proliferation as shown in
Additional file 1: Table S1. We initially evaluated the
Fig. 2 Palbociclib modulates the activation/expression of cell cycle-related proteins in a dose- and time-dependent manner. MDA-MB-231 and
HCC38 cells were treated with increasing concentrations of palbociclib for 24 h (a) or with a fixed drug concentration for different periods of time
(b). The expression of the indicated proteins was analyzed by Western blotting. Results are representative of three independent experiments
Fig. 3 Palbociclib up-regulates the PI3K/AKT/mTOR pathway in TNBC cells. MDA-MB-231 and HCC38 cells were treated with increasing concentrations
of palbociclib for 24 h (a) or with a fixed drug concentration for different periods of time (b). Then, the expression of the indicated proteins
was analyzed by Western blotting. Results are representative of three independent experiments
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simultaneous combination of increasing concentrations
of the PI3K/mTOR inhibitors with a fixed concentration
of palbociclib (0.5 μM) on MDA-MB-231 (Fig. 4a-c) and
HCC-38 cells (Fig. 4d-f ). Such combination gave rise to
an additive effect according to Bliss experimental model.
Since AKT activation increased up to 24 h of treatment
with palbociclib, we then evaluated the efficacy of a
combinatory schedule involving a pre-incubation with
palbociclib for 24 h followed by a simultaneous treat-
ment with the PI3K inhibitors plus palbociclib for fur-
ther 48 h (sequential combined treatment). As shown in
Fig. 5a-f, this sequential combined approach resulted in
a synergistic inhibition of cell proliferation in both
MDA-MB-231 and HCC-38 cells. Of note, when
palbociclib was removed during treatment with PI3K in-
hibitors the synergism was lost, resulting in an additive
inhibition of cell proliferation (Additional file 2:
Figure S1). The sequential combined treatment was asso-
ciated with a greater increase of the percentage of cells ac-
cumulating in the G0/G1 cell cycle phase (Fig. 5g), with
values of ~ 90% for all the PI3K inhibitors used. In
addition, the sequential combined treatment induced a
stronger down-regulation of the PI3K/AKT/mTOR path-
way, as shown by the inactivation of mTOR (Fig. 5h), to-
gether with a complete dephosphoryation of p-Rb, in
comparison with the single drug treatments. Moreover, in
these conditions myc expression was strongly inhibited
due to Rb inactivation. Directly comparing the growth-
Fig. 4 A simultaneous treatment with palbociclib and PI3K/AKT/mTOR inhibitors induces additive effects. MDA-MB-231 (a-c) and HCC38 cells (d-f)
were treated with 0.5 μM palbociclib alone or in combination with increasing concentrations of BYL719, BEZ235 or BKM120. After 72 h cell proliferation
was assessed by CV assay. The effect of the drug combinations was evaluated using the Bliss interaction model. Data are mean values ±SD of three
independent experiments (n = 5)
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inhibitory effects induced by the three different schedules
of treatment, we confirmed the superior efficacy of the se-
quential combined treatment over the others (23% of cell
proliferation vs 43–44% for the combined and the sequen-
tial treatments); in addition, palbociclib alone did not in-
duce cell death, as expected, mainly exerting a cytostatic
Fig. 5 A sequential exposure to palbociclib and PI3K/AKT/mTOR inhibitors, with palbocilcib maintained during all the treatment, induces synergistic
effects. MDA-MB-231 (a-c) and HCC38 cells (d-f) were pre-incubated with 0.5 μM palbociclib for 24 h. Then, the cells were treated with increasing
concentrations of BYL719, BEZ235 or BKM120 alone or in combination with palbociclib. After 48 h cell proliferation was assessed by CV
assay. The effect of the drug combinations was evaluated using the Bliss interaction model. Data are mean values ±SD of three independent experiments
(n = 5). g MDA-MB-231 cells were treated with 0.5 μM palbociclib for 48 h, 2.5 μM BYL719, 2.5 μM BKM120 or 50 nM BEZ235 for 24 h or
were pre-incubated with palbocilcib for 24 h and then with palbociclib combined with the PI3K/mTOR inhibitors for further 24 h. Then
the cells were stained with PI and the distribution of cells in cell cycle phases was determined by flow cytometry. Results are representative of three
independent experiments (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 vs G0/G1 ctrl; #p < 0.05 vs G0/G1 Palb; §§§p < 0.001 vs G0/G1 BYL719, BEZ235 or
BKM120. h The cells were treated as in g and the expression of the indicated proteins was evaluated on cell protein extracts by Western blotting.
Results are representative of two independent experiments
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effect; however, its combination with BEZ235 potentiate
the pro-apoptotic effects associated with PI3K/AKT/
mTOR inhibition, with the sequential combined treatment
showing the stronger cell death induction (31% of cell
death vs 15% and 21% for the combined and the sequen-
tial treatment, respectively) (Fig. 6a,b).
Taken together these results indicate that palbociclib
may be used to potentiate the anti-tumor activity of
PI3K inhibitors, and suggest the relevance of maintain-
ing palbociclib during treatment with these inhibitors to
provide the greatest benefit for TNBC.
Effect of palbociclib and PI3K/mTOR inhibition on glucose
energy metabolism
A variety of evidence indicates that cell cycle-related
proteins are directly involved in the regulation of cell en-
ergy metabolism [24]. Therefore, we evaluated the effect
of palbociclib, alone or combined with BYL719, on cell
glucose metabolism under both normoxic and hypoxic
conditions (Fig. 7a-d). Palbociclib down-regulated glu-
cose uptake and consumption, as well as the expression
of GLUT-1 glucose transporter in MDA-MB-231 cells,
and combination with BYL719 enhanced these inhibitory
effects under normoxic conditions. In particular, palboci-
clib induced ~ 15% decrease in glucose uptake and con-
sumption, the same produced by the treatment with
BYL719 alone; a higher decrease (25%) was promoted by
the drug combination. Exposure to hypoxia for 24 h in-
duced the stabilization and accumulation of HIF-1α and
up-regulated the expression of GLUT-1, resulting in a
significant increase of glucose utilization. Again, the
combination of palbociclib with BYL719 hindered
hypoxia-mediated stimulation of glucose uptake more
efficaciously than individual treatments (40% decrease vs
25% after palbociclib or BYL719 single treatment). Simi-
lar effects were observed for glucose consumption. The
greater efficacy of such combination was presumably as-
cribed to the inhibition of both PI3K/mTOR signaling
and c-myc expression (see Fig. 5h), whose involvement
in the modulation of glucose metabolism is well-
recognized [25]. Interestingly, the sequential combined
treatment with palbociclib maintained during the incu-
bation with BYL719 promoted a ~ 50% decrease of glu-
cose uptake as compared to control (Fig. 7e), which was
associated with a significant inhibition of GLUT-1 ex-
pression (Fig. 7f ).
Altogether these results suggest that inhibition of
PI3K/mTOR signaling may improve the efficacy of pal-
bociclib also through a negative modulation of glucose
metabolism.
Discussion
In the present study we demonstrate that CDK4/6 inhib-
ition by palbociclib in combination with PI3K/mTOR in-
hibitors may be an effective strategy for treatment of Rb-
proficient TNBC, affecting both cell proliferation/viabil-
ity and energy metabolism.
A functional Rb pathway is more frequently found in
luminal A hormone-positive BC, and preclinical data
have indicated these tumors as exquisitely sensitive to
CDK4/6 inhibition, providing the basis for the develop-
ment of novel therapeutic strategies for this BC subtype
[22]. Actually, palbociclib has received accelerated ap-
proval for first-line treatment in combination with letro-
zole or fulvestrant in postmenopausal women with
ERα+/HER2 − locally advanced or metastatic BC. In con-
trast, TNBC has been considered less likely to respond
to CDK4/6 inhibitors [22], being frequently associated
Fig. 6 The combination of palbociclib with BEZ235 enhances cell death. MDA-MB-231 cells were treated with 0.5 μM palbociclib, 50 nM BEZ235
or with three schedules of treatments: simultaneous, sequential or sequential combined. After 72 h, cell proliferation was evaluated by cell counting
with trypan blue exclusion (a) and cell death was assessed by fluorescence microscopy after Hoechst 3342/PI staining (b). Results are representative of
three independent experiments (n = 5). ***p < 0.001 vs ctrl; #p < 0.05, ###p < 0.001 vs palb; §p < 0.05, §§§p < 0.001 vs BEZ235; ▪▪▪p < 0.001 vs P + BEZ235;
●●●p < 0.001 vs P➔BEZ235
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with Rb loss [26]. However, a number of preclinical data
have been suggesting that palbociclib treatment may
provide benefit also in a proportion of TNBC [12, 27].
Here we show that palbociclib as a single-agent treat-
ment reduced cell proliferation in TNBC cell models, by
eliciting reversible blockade of the cell cycle in G1 phase.
This effect was observed only in cell lines expressing the
predictive markers of response to palbociclib, i.e. Rb,
cyclin D1, and CDK6 proteins, associated with undetect-
able levels of p16INK4. Palbociclib treatment in these
cells inhibited p-Rb, Rb, and p-CDK6 levels, and more
interestingly down-regulated the expression of c-myc, a
direct target of E2F transcription factor. Very recently,
CDK4 has been found highly expressed in TNBC, espe-
cially in the basal-like subtype [27], and this feature may
serve as an additional predictive marker of response to
Fig. 7 Palbociclib combined with the PI3K/AKT inhibitor BYL719 hinders glucose metabolism under normoxic and hypoxic conditions. MDA-MB-
231 cells were treated with 0.5 μM palbociclib and 5 μM BYL719 alone or in combination under normoxic or hypoxic (1% O2) conditions for 24 h.
Glucose uptake (a) and glucose consumption (b) were measured. *p < 0.05, **p < 0.01, ***p < 0.001 vs ctrl Normoxia (N); ●p < 0.05, ●●p < 0.01 vs
palb N; ▪p < 0.05, ▪▪p < 0.01 vs BYL N; ##p < 0.01, ###p < 0.001 vs ctrl Hypoxia (H); §§p < 0.01 vs Palb H; $$$p < 0.001 vs BYL H. c The expression of the
indicated proteins was analyzed by Western blotting. d GLUT-1 mRNA levels were analyzed by RT-PCR. Results are plotted as 2^-ΔΔCT ± SD. e
MDA-MB-231 cells were treated with 0.5 μM palbociclib for 48 h and 5 μM BYL719 for 24 h alone or were pre-incubated with palbocilcib for 24 h
and then with palbociclib combined with BYL719 for further 24 h. Glucose uptake was then evaluated. **p < 0.01, ***p < 0.001 vs ctrl; ###p < 0.001
vs palb; §§§p < 0.001 vs BYL. f The cells were treated as in e and GLUT-1 expression was evaluated by Western blotting on cell protein extracts. Data in
a,b and e are mean values ±SD of three independent experiments (n = 6). Data in d are mean values ±SD of three independent experiments (n = 4).
Results in c and f are representative of two independent experiments
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palbociclib in this type of BC. Blocking CDK4 expression
or activity in TNBC cells has been shown to prevent BC
stem cell self-renewal [27], thus providing a further ra-
tionale for exploiting palbociclib as a therapy for TNBC.
In addition, it has been recently demonstrated, in BC
cell lines including TNBC cells, that treatment with
CDK4/6 inhibitors triggers anti-tumor immunity by en-
hancing tumor antigen presentation and suppressing
regulatory T cells proliferation [28], thus opening new
perspectives in the use of CDK4/6 inhibitors in associ-
ation with immunotherapies.
In our study, palbociclib treatment gave the most
promising results when combined with PI3K/mTOR
inhibitors.
A relevant feature of palbociclib treatment is the in-
duction of AKT activation, through the release of p-Rb-
mediated suppression of mTORC2. Hyperphosphory-
lated Rb inhibits the activity of the mTORC2 complex,
by directly binding to the complex component Sin1.
Since AKT is a substrate of mTORC2, the inhibition of
Rb phosphorylation, associated with CDK4/6 inhibition,
results in mTORC2 activation, thus increasing AKT acti-
vation [13].
This provided a rationale for evaluating the efficacy of
combining palbociclib with PI3K/mTOR inhibitors fol-
lowing different schedules of treatment: a simultaneous
combination, a sequential treatment in which a pre-
incubation with palbociclib was followed by treatment
with PI3K/mTOR inhibitors alone, or a sequential com-
bined treatment in which palbociclib, given as a pre-
treatment, was also maintained during exposure to
PI3K/mTOR inhibitors. The latter schedule produced a
synergistic growth inhibitory effect as calculated by the
Bliss experimental model, whereas an additive effect was
observed with the other two schedules.
The synergistic effect of the association of palbociclib
and PI3K inhibitors has been recently reported for lu-
minal androgen receptor-positive TNBC cell lines and
has been associated with low level of CDK2 activity, ra-
ther than with p16INK4 loss and cyclin D1 expression
[12]. Here we show that also other TNBC subtypes, i.e.
mesenchymal and basal-like subgroups, represented by
MDA-MB-231 and HCC38 cell models respectively [29],
may benefit from a combined therapy with palbociclib
and PI3K/mTOR inhibitors, provided that they express
the predictive factors of response to palbociclib. Import-
antly, our results demonstrate that the sequential com-
bined treatment of palbociclib and PI3K/mTOR
inhibitors is more effective than simultaneous treatment
and might therefore represent a novel therapeutic ap-
proach for the treatment of TNBC of different cell
subtypes.
Aberrant energy metabolism is an important hallmark
of cancer, that is being exploited as a therapeutic target
[30]. Here we provide evidence that inhibition of glucose
metabolism may contribute to palbociclib anti-tumor ac-
tivity in TNBC cells. The cyclin D1/CDK6/Rb/E2F path-
way has been involved in the control of a variety of
metabolic processes, such as glucose production and
glycolytic metabolism, indicating a close relationship
between metabolic responses and proliferative stimuli
[31]. There is evidence that E2F pathway is a negative
regulator of energy expenditure, through repression of
mitochondrial oxidative metabolism [24]; E2F is also
able to stimulate the glycolytic flux through regulation
of phosphofructokinase enzyme expression [24]. In
addition, downstream of E2F, c-myc transcription
factor may affect cancer metabolic reprogramming
through a variety of mechanisms, and in particular it
has been shown to drive glucose metabolism in TNBC
cells [32].
Here we demonstrate that palbociclib-mediated inhib-
ition of E2F/c-myc hinders glucose metabolism in TNBC
cells, by inhibiting GLUT-1 expression and glucose up-
take under both normoxic and hypoxic conditions. c-
Myccooperates with HIF-1 to induce the expression of
glycolytic enzymes [33]; interestingly, palbociclib inhib-
ited also hypoxia-induced HIF-1α accumulation, which
might contribute to reduce glucose utilization under
hypoxia. This result is in line with a recent study show-
ing that palbociclib destabilizes HIF-1α in colon cancer
cells under either normoxic or hypoxic conditions [34].
In our study, the inhibitory effects of palbociclib on glu-
cose metabolism were further enhanced by the combin-
ation with PI3K/mTOR inhibitors, being the AKT/
mTOR signaling another key player in cancer metabolic
reprogramming [35]. Accordingly, palbociclib combined
with the mTOR inhibitor everolimus has been recently
demonstrated to inhibit aerobic glycolysis in glioblast-
oma cells [36]. Importantly, we observed a strong im-
pairment of glucose metabolism when the combination
with palbociclib and PI3K/mTOR inhibitors was pre-
ceded by treatment with palbociclib alone, likely contrib-
uting to the synergistic anti-tumor effects associated
with this schedule of treatment.
Conclusions
In conclusion, our study provides a pre-clinical rationale
for the combination of palbociclib with PI3K/mTOR in-
hibitors as a therapeutic strategy for TNBC, highlighting
the superior efficacy of the sequential combined sched-
ule of treatment. A limitation of this study is that these
results were obtained in in vitro experiments and would
require confirmation in vivo in animal models, also to
ascertain whether palbocilcib may be safely maintained
during treatment with PI3K/mTOR inhibitors in order
to produce synergistic anti-tumor effects without wors-
ening toxicity.
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Additional files
Additional file 1: Table S1. Sensitivity of TNBC cells to PI3K/mTOR
inhibitors. HCC38 cells and MDA-MB-231 cells were treated with
increasing concentrations of the indicated PI3K/mTOR inhibitors. After
72h cell proliferation was evaluated by CV staining. Data are expressed
as EC50 values and are means ±SD of three independent expreiments
(n = 5). (TIFF 371 kb)
Additional file 2: Figure S1. A sequential exposure to palbociclib
followed by PI3K/AKT/mTOR inhibitors alone induces additive effects.
MDA-MB-231 were pre-incubated with 0.5 μM palbociclib for 24h and
then treated with increasing concentrations of BYL719 (a), BEZ235 (b) or
BKM120 (c) alone. After 48h cell proliferation was assessed by CV assay.
The effect of the drug combinations was evaluated using the Bliss
interaction model. Data are mean values ±SD of three insdependent
experiments (n = 5). (TIFF 437 kb)
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